- Home
- GPRE vs DNTH Comparison
GPRE vs DNTH Comparison
Compare GPRE & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRE
- DNTH
- Stock Information
- Founded
- GPRE 2004
- DNTH 2015
- Country
- GPRE United States
- DNTH United States
- Employees
- GPRE N/A
- DNTH N/A
- Industry
- GPRE Major Chemicals
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- GPRE Industrials
- DNTH Health Care
- Exchange
- GPRE Nasdaq
- DNTH Nasdaq
- Market Cap
- GPRE 790.7M
- DNTH 823.1M
- IPO Year
- GPRE N/A
- DNTH N/A
- Fundamental
- Price
- GPRE $11.09
- DNTH $20.27
- Analyst Decision
- GPRE Strong Buy
- DNTH Strong Buy
- Analyst Count
- GPRE 9
- DNTH 8
- Target Price
- GPRE $26.06
- DNTH $46.43
- AVG Volume (30 Days)
- GPRE 1.4M
- DNTH 291.2K
- Earning Date
- GPRE 10-31-2024
- DNTH 11-07-2024
- Dividend Yield
- GPRE N/A
- DNTH N/A
- EPS Growth
- GPRE N/A
- DNTH N/A
- EPS
- GPRE N/A
- DNTH N/A
- Revenue
- GPRE $2,587,166,000.00
- DNTH $5,366,000.00
- Revenue This Year
- GPRE N/A
- DNTH $44.94
- Revenue Next Year
- GPRE $6.02
- DNTH N/A
- P/E Ratio
- GPRE N/A
- DNTH N/A
- Revenue Growth
- GPRE N/A
- DNTH 51.41
- 52 Week Low
- GPRE $10.36
- DNTH $6.58
- 52 Week High
- GPRE $28.50
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- GPRE 44.61
- DNTH 22.81
- Support Level
- GPRE $10.36
- DNTH $22.19
- Resistance Level
- GPRE $11.37
- DNTH $28.56
- Average True Range (ATR)
- GPRE 0.64
- DNTH 2.02
- MACD
- GPRE -0.03
- DNTH -0.88
- Stochastic Oscillator
- GPRE 21.01
- DNTH 3.38
About GPRE Green Plains Inc.
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in three segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities. The partnership segment provides fuel storage and transportation services.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.